Podcast
MSL Talk: Tom Caravela, Linda Traylor, Rena Patel
Why and How to Build a “Community” MSL Team
Summary
In this episode, Bobby Faison joins to discuss the concept and implementation of community MSL teams. The conversation highlights the importance of building these teams, their roles in KOL mapping, and effective engagement strategies. Bobby covers essential aspects such as hiring, qualifications, and entry-level opportunities for community MSLs, alongside the challenges they face. The episode delves into the dynamics between community MSLs and commercial teams, territory management, and travel considerations. Bobby also examines the metrics for assessing the community MSL model's success and offers career advancement advice. The episode concludes with insights into customer segmentation and its impact on field medical teams.
My guest today is Bobby Faison, Executive Director, Medical Affairs with Paratek Pharmaceuticals. Bobby discusses why and how to build a “Community” MSL team.
Bobby shares…
👉 What is a “Community” MSL
👉 How a “Community” MSL is different from a traditional, therapeutic MSL
👉 What the relationship with commercial looks like
👉 What the expectations are for “Community” MSLs in regard to metrics and KPIs
👉 Advice for organizations looking to implement this model
👉 Why the Community MSL role is a great pathway for Aspiring MSLs
Community MSL teams, KOL mapping, community MSL roles, engagement strategies, MSL career advancement
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Linda Traylor, Rena Patel
Podcast
MSL Talk: Tom Caravela, Omar McMillan
Digital Opinion Leaders: What You Should Know About DOLs
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary